Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells

Yan,Kun-Huang; Lee,Liang-Ming; Hsieh,Mao-Chih; Yan,Ming-De; Yao,Chih-Jung; Chang,Pey-Yi; Chen,Tsung-Li; Chang,Hwan-You; Cheng,Ann-Lii; Lai,Gi-Ming; Chuang,Shuang-En

doi:10.3892/or.2013.2561

Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells

Authors:
- Kun-Huang Yan
- Liang-Ming Lee
- Mao-Chih Hsieh
- Ming-De Yan
- Chih-Jung Yao
- Pey-Yi Chang
- Tsung-Li Chen
- Hwan-You Chang
- Ann-Lii Cheng
- Gi-Ming Lai
- Shuang-En Chuang
View Affiliations

Affiliations: Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, R.O.C., Division of General Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, R.O.C., National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan, R.O.C., Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, R.O.C., Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, Taiwan, R.O.C., Departments of Internal Medicine and Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
Published online on: June 21, 2013 https://doi.org/10.3892/or.2013.2561
Pages: 1497-1505

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Methotrexate (MTX) has been widely used for the treatment of cancer and rheumatoid arthritis (RA). Aspirin (ASA) is a non-selective cyclooxygenase (COX) inhibitor that contributes to the treatment of inflammatory conditions such as RA. It has been observed that the antitumor effect of ASA can be attributed to inhibition of cell cycle progression, induction of apoptosis and inhibition of angiogenesis. In the present study, we revealed that the treatment with a combination of MTX and ASA resulted in antagonism of the cytotoxic effect as demonstrated by SRB and colony formation assays. ASA alleviated the MTX-mediated S phase accumulation and recovered the G1 phase. MTX-mediated accumulation of the S phase marker cyclin A was also alleviated by ASA. Notably, FAS protein levels were upregulated by MTX in A549 cells. The antagonism of MTX efficacy caused by ASA was accompanied by altered expression of caspase-3, Bcl-2 and FAS but not dihydrofolate reductase (DHFR). This suggests that the alteration of caspase-3, Bcl-2 and FAS was involved in the antagonism between ASA and MTX. Exogenously added folic acid reversed the MTX-mediated DHFR inhibition following either MTX or MTX + ASA treatments. Most importantly, we demonstrated for the first time that the commonly used non-steroidal anti-inflammatory drug for headache ASA and possibly other COX-1/2 inhibitors can produce a strong antagonistic effect on the growth inhibition of lung cancer cells when administered in combination with MTX. The clinical implication of our finding is obvious, i.e., the clinical efficacy of MTX therapy can be compromised by ASA and their concomitant use should be avoided.

View Figures

View References

1	Fotoohi AK and Albertioni F: Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma. 49:410–426. 2008. View Article : Google Scholar : PubMed/NCBI
2	Hider SL, Bruce IN and Thomson W: The pharmacogenetics of methotrexate. Rheumatology. 46:1520–1524. 2007. View Article : Google Scholar
3	Yamauchi A, Ichimiya T, Inoue K, Taguchi Y, Matsunaga N, Koyanagi S, Fukagawa T, Aramaki H, Higuchi S and Ohdo S: Cell-cycle-dependent pharmacology of methotrexate in HL-60. J Pharmacol Sci. 99:335–341. 2005. View Article : Google Scholar : PubMed/NCBI
4	Cronstein BN: Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 57:163–172. 2005. View Article : Google Scholar : PubMed/NCBI
5	Tian H and Cronstein BN: Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 65:168–173. 2007.PubMed/NCBI
6	Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN and Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 312:818–822. 1985. View Article : Google Scholar : PubMed/NCBI
7	Chan ES and Cronstein BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 4:266–273. 2002. View Article : Google Scholar : PubMed/NCBI
8	Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, Huizinga TW and Guchelaar HJ: A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56:1765–1775. 2007. View Article : Google Scholar : PubMed/NCBI
9	Hani N, Casper C, Groth W, Krieg T and Hunzelmann N: Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease. Eur J Dermatol. 10:548–550. 2000.PubMed/NCBI
10	Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A and Roy P: Chemotherapy-induced and/or radiation therapy-induced oral mucositis - complicating the treatment of cancer. Neoplasia. 6:423–431. 2004. View Article : Google Scholar : PubMed/NCBI
11	Tomoda R, Seto M, Hioki Y, Sonoda J, Matsumine A, Kusuzaki K and Uchida A: Low-dose methotrexate inhibits lung metastasis and lengthens survival in rat osteosarcoma. Clin Exp Metastasis. 22:559–564. 2005. View Article : Google Scholar : PubMed/NCBI
12	Morison WL, Momtaz K, Parrish JA and Fitzpatrick TB: Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol. 6:46–51. 1982. View Article : Google Scholar : PubMed/NCBI
13	Sweeney CJ, Takimoto CH, Latz JE, Baker SD, Murry DJ, Krull JH, Fife K, Battiato L, Cleverly A, Chaudhary AK, Chaudhuri T, Sandler A, Mita AC and Rowinsky EK: Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clin Cancer Res. 12:536–542. 2006. View Article : Google Scholar : PubMed/NCBI
14	Pablos JL: Aspirin antiplatelet therapy and nonsteroidal antiinflammatory drugs: comment on the 2002 update of the American College of Rheumatology Guidelines for the Management of Rheumatoid Arthritis. Arthritis Rheum. 46:31022002. View Article : Google Scholar
15	Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, Cummings KM, Falkner KL, Loewen GM and Bepler G: Regular aspirin use and lung cancer risk. BMC Cancer. 2:312002. View Article : Google Scholar : PubMed/NCBI
16	Van Dyke AL, Cote ML, Prysak G, Claeys GB, Wenzlaff AS and Schwartz AG: Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev. 17:148–157. 2008.PubMed/NCBI
17	Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ and Thun M: Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10:501–507. 2009. View Article : Google Scholar : PubMed/NCBI
18	Kremer JM and Hamilton RA: The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol. 22:2072–2077. 1995.
19	Stewart CF, Fleming RA, Germain BF, Seleznick MJ and Evans WE: Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum. 34:1514–1520. 1991. View Article : Google Scholar : PubMed/NCBI
20	Fries JF, Singh G, Lenert L and Furst DE: Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum. 33:1611–1619. 1990. View Article : Google Scholar : PubMed/NCBI
21	Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R and Wu CW: Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol. 17:353–360. 1997. View Article : Google Scholar : PubMed/NCBI
22	Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B and Pinedo HM: Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer. 27:897–900. 1991. View Article : Google Scholar : PubMed/NCBI
23	Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58:621–681. 2006. View Article : Google Scholar : PubMed/NCBI
24	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
25	Yan KH, Yao CJ, Chang HY, Lai GM, Cheng AL and Chuang SE: The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol Carcinog. 49:235–246. 2010.PubMed/NCBI
26	Rooney TW, Furst DE, Koehnke R and Burmeister L: Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol. 20:1297–1302. 1993.PubMed/NCBI
27	Kurth T, Hennekens CH, Buring JE and Gaziano JM: Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis. Curr Rheumatol Rep. 6:351–356. 2004. View Article : Google Scholar : PubMed/NCBI
28	Ranganathan P: An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics. 9:439–451. 2008. View Article : Google Scholar : PubMed/NCBI
29	Krajinovic M and Moghrabi A: Pharmacogenetics of methotrexate. Pharmacogenomics. 5:819–834. 2004. View Article : Google Scholar
30	Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, Domann FE and Trask DK: Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. Mol Carcinog. 46:857–864. 2007. View Article : Google Scholar : PubMed/NCBI
31	Janssen A, Maier TJ, Schiffmann S, Coste O, Seegel M, Geisslinger G and Grösch S: Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol. 540:24–33. 2006. View Article : Google Scholar : PubMed/NCBI
32	Resnitzky D, Hengst L and Reed SI: Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Mol Cell Biol. 15:4347–4352. 1995.PubMed/NCBI
33	Mateo F, Vidal-Laliena M, Canela N, Busino L, Martinez-Balbas MA, Pagano M, Agell N and Bachs O: Degradation of cyclin A is regulated by acetylation. Oncogene. 28:2654–2666. 2009. View Article : Google Scholar : PubMed/NCBI
34	Gloire G, Charlier E and Piette J: Regulation of CD95/APO-1/Fas-induced apoptosis by protein phosphatases. Biochem Pharmacol. 76:1451–1458. 2008. View Article : Google Scholar : PubMed/NCBI
35	Mollinedo F and Gajate C: Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat. 9:51–73. 2006. View Article : Google Scholar : PubMed/NCBI
36	Kim R, Emi M, Tanabe K, Uchida Y and Toge T: The role of Fas ligand and transforming growth factor β in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 100:2281–2291. 2004.
37	O’Brien DI, Nally K, Kelly RG, O’Connor TM, Shanahan F and O’Connell J: Targeting the Fas/Fas ligand pathway in cancer. Expert Opin Ther Targets. 9:1031–1044. 2005.
38	Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, Huvos A, Banerjee D, Bertino JR and Gorlick R: mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther. 2:535–541. 2003.
39	Slansky JE, Li Y, Kaelin WG and Farnham PJ: A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol. 13:1610–1618. 1993.PubMed/NCBI
40	Skacel N, Menon LG, Mishra PJ, Peters R, Banerjee D, Bertino JR and Abali EE: Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate treatment. J Biol Chem. 280:22721–22731. 2005. View Article : Google Scholar : PubMed/NCBI
41	Mishra PJ, Humeniuk R, Longo-Sorbello GS, Banerjee D and Bertino JR: A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA. 104:13513–13518. 2007. View Article : Google Scholar : PubMed/NCBI
42	Snijders AM, Hermsen MA, Baughman J, Buffart TE, Huey B, Gajduskova P, Roydasgupta R, Tokuyasu T, Meijer GA, Fridlyand J and Albertson DG: Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability. Genes Chromosomes Cancer. 47:71–83. 2008. View Article : Google Scholar : PubMed/NCBI
43	Bertino JR, Göker E, Gorlick R, Li WW and Banerjee D: Resistance mechanisms to methotrexate in tumors. Stem Cells. 14:5–9. 1996. View Article : Google Scholar
44	Ercikan-Abali EA, Banerjee D, Waltham MC, Skacel N, Scotto KW and Bertino JR: Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region. Biochemistry. 36:12317–12322. 1997. View Article : Google Scholar : PubMed/NCBI
45	Hsieh YC, Skacel NE, Bansal N, Scotto KW, Banerjee D, Bertino JR and Abali EE: Species-specific differences in translational regulation of dihydrofolate reductase. Mol Pharmacol. 76:723–733. 2009. View Article : Google Scholar : PubMed/NCBI